Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05856994 · ClinicalTrials.gov registry record · Phase 1

Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns

A Phase 1 study of Burn Injury, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT05856994 is a Phase 1 study of Burn Injury that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 18 participants, below the 41-participant average among 10 other Burn Injury trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05856994, a Phase 1 study of Burn Injury, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

There is currently no standard treatment to prevent burn depth conversion in partial-thickness burns. Conversion into deeper wounds is associated with higher complications and morbidity. The most common theory attributes this depth conversion to the prolonged inflammatory response that occurs after burn injury. Therefore, the investigators propose testing the safety and efficacy of tacrolimus ointment (an immunosuppressive agent) in patients with deep partial-thickness burns.

Conditions Studied

Interventions

  • DRUG Tacrolimus ointment

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2024-09-19
Est. Completion 2028-06-01
Phase Phase 1

What the Registry Record Tells You About NCT05856994

The ClinicalTrials.gov registry entry for NCT05856994 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 10 other Burn Injury trials with a reported enrollment target (56% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Burn Injury appearing as the primary indexed condition, and to 1 intervention - of which Tacrolimus ointment is the first listed.

NCT05856994 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT05856994 about?

NCT05856994 is a clinical study titled "Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns". There is currently no standard treatment to prevent burn depth conversion in partial-thickness burns. Conversion into deeper wounds is associated with higher complications and morbidity. The most common theory attributes this depth conversion to the prolonged inflammatory response that occurs after ...

What is the current status of trial NCT05856994?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-09-19. Estimated completion is 2028-06-01.

What conditions does trial NCT05856994 study?

This clinical trial studies the following conditions: Burn Injury.

What interventions are being tested in trial NCT05856994?

The interventions under investigation include: Tacrolimus ointment (DRUG).

Who is sponsoring clinical trial NCT05856994?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05856994 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Burn Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.